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Signaling proteins driving the proliferation of stem
and progenitor cells are often encoded by proto-
oncogenes. EphB receptors represent a rare excep-
tion; they promote cell proliferation in the intestinal
epithelium and function as tumor suppressors by
controlling cell migration and inhibiting invasive
growth. We show that cell migration and proliferation
are controlled independently by the receptor EphB2.
EphB2 regulated cell positioning is kinase-indepen-
dent andmediated via phosphatidylinositol 3-kinase,
whereas EphB2 tyrosine kinase activity regulates cell
proliferation through an Abl-cyclin D1 pathway.
Cyclin D1 regulation becomes uncoupled from EphB
signaling during the progression from adenoma to
colon carcinoma in humans, allowing continued
proliferation with invasive growth. The dissociation
of EphB2 signaling pathways enables the selective
inhibition of the mitogenic effect without affecting
the tumor suppressor function and identifies a phar-
macological strategy to suppress adenoma growth.
INTRODUCTION
Essential pathways regulating cell proliferation are often shared
between stem/progenitor cells and cancer cells. This poses
a problem as these pathways cannot be targeted to specifically
eliminate tumor cells without simultaneously risking the deple-
tion of untransformed cells, which is often a limiting factor in
chemotherapy when doses that may eradicate tumor cells give
unacceptable side effects. EphB receptors represent a rare
exception in that they promote proliferation in the normal intes-tinal epithelium but, paradoxically, act as tumor suppressors in
colon cancer development (Batlle et al., 2005; Holmberg et al.,
2006). How can the same protein drive proliferation in the normal
situation and function as a tumor suppressor in the same tissue?
Eph receptors constitute the largest subgroup of tyrosine
kinase receptors. Their ephrin ligands, which are either trans-
membrane proteins or attached to the cell membrane with
a GPI anchor, are also capable of signaling. Eph receptors and
ephrins are best known for their roles in controlling cell migration
and axon guidance (Pasquale, 2008), but have more recently
been identified as regulators of stem and progenitor cell prolifer-
ation (Chumley et al., 2007; Depaepe et al., 2005; Holmberg
et al., 2005, 2006; Jiao et al., 2008; Ricard et al., 2006). The
molecular mechanisms for Eph/ephrin-mediated regulation of
stem/progenitor cell proliferation are unknown. In the intestinal
epithelium, EphB receptors regulate both cell migration and
progenitor cell proliferation (Batlle et al., 2002; Holmberg et al.,
2006). Cell migration is deranged in the intestinal epithelium in
mice lacking EphB2 and EphB3, and the absence of EphB
signaling results in up to a 50% reduction in the number of prolif-
erating cells (Batlle et al., 2002; Holmberg et al., 2006).
EphB receptor expression is highly increased in intestinal
adenomas (Batlle et al., 2002). EphB signaling regulates adhe-
rens junction formation and promotes compartmentalization of
colorectal cancer cells, and in this way suppresses cancer
progression by inhibiting invasive growth (Cortina et al., 2007).
EphB expression is almost invariably lost during progression to
carcinoma and initiation of invasive growth (Batlle et al., 2005;
Guo et al., 2005; Jubb et al., 2005), and the tumor suppressor
effect of EphB signaling is a consequence of its capacity to regu-
late cell migration (Cortina et al., 2007). It was unknown whether
EphB receptors employ the same signaling pathways to control
cell migration and mitosis, or if these functions are separate.
We here show that EphB2 regulates two separate signaling
pathways in the intestinal epithelium to control cell proliferationCell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc. 679
Figure 1. EphB Signaling Regulates Two Separate Transcriptional Programs
(A–C) Differentially expressed mRNAs 12 hr after inhibiting EphB signaling by an ephrin-B2-Fc injection cluster into two separate programs, cell cycle (blue frame
in B) and cell organization (yellow frame in B), by gene ontology classification. Significant gene ontology terms are indicated by red frame. Genes listed in (A) and
(C) belong to the indicated gene ontology terms. n = 4 mice in each group.
(D and E) Quantitative representation of expression levels (mean + SEM) of selected genes (names marked red in A and C) implicated in cell-cycle (D) or cyto-
skeletal (E) regulation relative to Fc injected animals.and migration. The identification of distinct EphB signaling path-
ways provides a pharmacological strategy to inhibit adenoma
growth.
RESULTS
Separate Transcriptional Programs for EphB-Mediated
Proliferation and Migration
To first gain a global view of the signaling pathways engaged by
EphB receptors in the intestinal epithelium, we analyzed tran-
scriptional alterations after acute inhibition of EphB signaling
in vivo. Eph receptors need to be clustered to signal and soluble
ephrins act as antagonists (Vearing and Lackmann, 2005). An
intravenous injection of ephrin-B2-Fc decreases EphB2 tyrosine
phosphorylation and results in a reduction in cell proliferation to
a similar extent as in EphB2; EphB3 double-null mutant mice
(Holmberg et al., 2006). Moreover, cells become mislocalized
along the crypt-villus axis, as in EphB2/; EphB3/ mice,
although this is not apparent until several days after injection of
the antagonist (Holmberg et al., 2006). By analyzing the tran-680 Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc.scriptome within the first day after blocking EphB signaling, it
is possible to study the effects of blocked EphB signaling without
the potential secondary effects caused by distorted cell posi-
tioning. Since ephrin-B2-Fc binds exclusively to EphB express-
ing cells in the crypts in the intestine (Holmberg et al., 2006), it
is possible to assess transcriptional alterations in these cells in
response to the EphB antagonist in whole preparations of colon.
An injection of ephrin-B2-Fc resulted in significant (p < 0.001)
differential expression of 739 transcripts after 3 hr and 910 tran-
scripts after 12 hr, as compared to Fc injected control animals.
Pairwise analyses followed by gene ontology classification iden-
tified alterations in two distinct transcriptional programs
(Figure 1, and Tables S1 and S2 available online). The majority
of differentially expressed messenger RNAs (mRNAs) clustered
either under themes related to cell-cycle regulation and progres-
sion or cell localization and cytoskeletal regulation (Figure 1B
and Table S2). The differentially expressed mRNAs that did not
cluster under these themes were related to general cellular
metabolism (Table S2). Although EphB forward signaling medi-
ates both proliferation and cell positioning (Holmberg et al.,
2006), some transcriptional changes may be caused by blocked
ephrin-B reverse signaling.
Many of the transcripts involved in cell-cycle progression were
reduced by approximately 50% at 12 hr after ephrin-B2-Fc injec-
tion (Figures 1A and 1D), quantitatively corresponding to the
reduction in the number of proliferating cells in the crypts in the
absence of EphB signaling (Holmberg et al., 2006). The expres-
sion of many of these genes was largely unaffected 3 hr after
blocking EphB signaling, suggesting that their lower expression
at 12 hr may be an effect of a reduced number of cells in cycle
rather than direct regulation by EphB signaling.
The transcriptional regulation of many migration- and cyto-
skeleton-associated genes tended to be deregulated earlier,
where inhibition of EphB signaling resulted in an altered expres-
sion at 3 hr that was sustained at 12 hr after injection of ephrin-
B2-Fc (Figures 1C and 1E). The segregation of transcriptional
changes after inhibition of EphB signaling into two distinct
sets, one associated with cell migration and one with mitosis,
provides a first indication that EphB receptors engage distinct
signaling pathways to control cell positioning and proliferation.
EphB2 Kinase Activity Is Necessary for Its Mitogenic
Effect but Is Dispensable for Cell Positioning
We have generated a series of mutant mice carrying different
substitutions in the EphB2 intracellular domain in an attempt to
identify domains in the EphB2 receptor that regulate migration
and proliferation. See Figure 2 for a schematic depiction of
EphB2 variants and Figures S1–S3 for targeting strategies. Since
EphB2 and EphB3 are partly redundant in regulating proliferation
and migration in the intestine (Batlle et al., 2002; Holmberg et al.,
2006), theanalyseswereperformedonanEphB3null background.
Exchange of the intracellular part of the EphB2 receptor with
b-galactosidase (Figure 2A) results in a receptor that is still
capable of binding and activating ligands expressed by neigh-
boring cells, but without being able to signal itself, thus allowing
for discrimination between forwardand reverse signaling (Henke-
meyer et al., 1996).Wepreviously demonstrated that substitution
of the intracellular domain with b-galactosidase leads to a reduc-
tion in proliferation and mispositioning of cells, establishing that
both the mitogenic and migration effects of EphB2 are mediated
through forward signaling (Holmberg et al., 2006) (Figure 2B). To
assess cellmigration andpositioning in aquantitativemanner,we
first focused on the differentiated Paneth cells, which normally
are situated exclusively at the bottom of the crypts in the small
intestine, but are mispositioned and spread throughout the
crypt-villus axis in the absence of EphB signaling (Batlle et al.,
2002; Holmberg et al., 2006). Paneth cells in EphB2 LacZ/LacZ;
EphB3/ mice were displaced to the same extent as in the
EphB2; EphB3 double-null mutant mice (Figures 2C and S4).
Kinase activity and binding of PDZ domain-containing proteins
to the Eph receptor PDZ binding motif located at the extreme
C terminus represent two distinct aspects of forward signaling.
We generated mice carrying mutations disrupting EphB2 kinase
activity (K661R) or its PDZ domain-binding motif (DVEV994), or
both in combination. Deletion of the last three amino acids of
EphB2 (DVEV994, see Figures S1A and S1B for targeting
strategy) renders the receptor incapable of binding PDZ
domain-containing proteins. The DVEV994 deletion does not
alter the level of EphB2 tyrosine phosphorylation, the distribution,
or the membrane localization of the EphB2 receptor in
the intestine (Figures S1C and S1D). Quantification of cell prolif-
eration and Paneth cell displacement revealed no significant
difference between EphB2 DVEV994/DVEV994; EphB3/ mice
compared to EphB2+/+; EphB3/ littermates (Figures 2B and
2C). The number of proliferating cells in each mouse line was
normalized to its wild-type control, giving the proliferation index.
Proliferation of intestinal progenitor cells is increased in mice
that express a constitutively active EphB2 receptor (Holmberg
et al., 2006), indicating that tyrosine kinase activity may be
important for the mitogenic effect. We introduced a point
Figure 2. EphB2 Kinase Activity Is Required for Its Mitogenic Effect but Is Dispensable for Cell Positioning
(A) Schematic depiction of wild-type EphB2 and modified receptors.
(B) Quantification of cell proliferation in colon crypts in adult mice with different EphB receptor modifications. The number of proliferating cells in each mouse line
was normalized to its wild-type control, giving the proliferation index. Kinase activity is required for the mitogenic effect of EphB2, whereas the PDZ domain-
binding C terminus is redundant. Broken lines indicate the levels for wild-type and EphB2: EphB3 double-null mice.
(C) Quantification of the distance of Paneth cells to the crypt base relative to wild-typemice. The intracellular domain of EphB2 is required, but both kinase activity
and the PDZ domain-binding C terminus are redundant, for cell positioning. Broken lines indicate the levels for wild-type and EphB2+/+; EphB3/mice. Repre-
sentative images for the cell proliferation and migration analyses are shown in the Supplemental Data. n = 3–8 mice in each group, except for the EphB2
K661RDVEV994/K661RDVEV994; EphB3/ mice, where n = 2.
Data are represented as mean + SEM. * p% 0.05, ** p% 0.01, and *** p% 0.001 compared to EphB2+/+; EphB3/ mice, Student’s t test.Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc. 681
mutation in the EphB2 gene (K661R) to express a kinase-dead
receptor that cannot convey kinase-dependent forward signals.
Analysis of colon tissue from EphB2 K661R/K661R homozygote
animals revealed an absence of EphB2 tyrosine phosphoryla-
tion, without any alteration in the expression level, membrane
localization, or distribution of EphB2 protein (Figures S2C and
S2D). The number of mitotic cells in intestinal crypts in EphB2
K661R/K661R; EphB3/ mice was reduced to a similar extent
as in EphB2/; EphB3/ mice. However, EphB2 K661R/
K661R; EphB3/ mice displayed no additional displacement
of Paneth, neuroendocrine, goblet, or progenitor cells compared
to EphB3/ mice (Figures 2B, 2C, and S4). This indicates that
EphB2 catalytic activity is important for conveying mitogenic,
but not positional, cues in the intestinal epithelium.
We also generated an EphB2mutantmouse that combines the
K661R and DVEV994 modifications (Figure 2A; see Figures S3A
and S3B for targeting strategy). The intestinal phenotype in these
mice was indistinguishable from mice that carry only the K661R
kinase inactivating mutation (Figures 2B and 2C). In total, anal-
ysis of these three new mutations in EphB2 indicates that the
mitogenic effect of EphB2 is kinase dependent, whereas regula-
tion of cell migration is mediated by kinase- and PDZ-indepen-
dent forward signaling.
EphB-Mediated Cell Positioning of Intestinal Cells Is
Conveyed by Phosphatidylinositol 3-Kinase
Kinase-independent functions of Eph receptor signaling have
previously been described in cell lines and were found to be
conveyed by phosphatidylinositol 3-kinase (PI3K) (Gu and
Park, 2001). As PI3K mediates cell migration signals by Eph
receptors in some contexts (Brantley-Sieders et al., 2004;
Maekawa et al., 2003), we asked whether EphB-mediated cell
positioning in the intestinal epitheliummay bemediated by PI3K.
We first assessed the role of PI3K in conveying repulsive
signals in intestinal cells in an in vitro assay. Ls174t colon carci-
noma cells, which express high levels of EphB2 and EphB3
(Batlle et al., 2002), were plated on a confluent mosaic of wild-
type 293t cells (which do not endogenously express ephrins or
Eph receptors) and 293t cells stably expressing ephrin-B2 and
GFP. Ls174t cells avoided the ephrin-B2-expressing cells and
were preferentially found on the wild-type 293t cells 12 hr after
plating (Figures 3A and 3B). However, the PI3K inhibitor
LY294002 reduced this response in a dose-dependent manner,
and at 5 mM the cells did not show any avoidance of ephrin-B2-
expressing cells (Figure 3A and 3B). This indicates that PI3K
activity is important for conveying positional information in
response to ephrin-B2 in intestinal cells.
We next studied the role of PI3K in cell positioning in the intes-
tinal epithelium in vivo. We administered the PI3K inhibitor
LY294002, ephrin-B2-Fc, or both in combination to adult mice
and assessed cell positioning in the intestinal epithelium 3 or 7
days later. Paneth cells showed a quantitatively similar displace-
ment after inhibiting PI3K or EphB signaling, and there was no
additive or synergistic effect of blocking both PI3K and EphB
signaling simultaneously (Figures 3C and 3D). Importantly, inhibi-
tion of PI3K activity had no effect on cell proliferation in the intes-
tinal epithelium (Figures 3E and 3F).682 Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc.The microarray analysis of gene expression in the intestine
(Figure 1) revealed expression of both isoforms of the regulatory
PI3K subunit, p85a and p85b, and two (out of four known) iso-
forms of the catalytic subunit, p110a and p110d (Figure S5).
p85a showed an approximately 4-fold higher expression than
p85b and p110a was expressed approximately 3-fold higher
than p110d (Figure S5). Inhibition of EphB signaling by an injec-
tion of ephrin-B2-Fc resulted in decreased expression of both
catalytic subunit isoforms, with the most dramatic deregulation
of p110a mRNA levels showing a 37% reduction after 3 hr (p =
0.0004) and 44% after 12 hr (p = 0.0006) (Figure S5). It is difficult
to formally exclude that LY294002 may modulate additional
substrates to PI3K, but the EphB-mediated regulation of expres-
sion of PI3K catalytic subunits corroborates the role for PI3K
downstream of EphB signaling in the intestine.
EphB Signaling Does Not Affect b-Catenin-Mediated
Transcription
To explore how EphB kinase activity promotes cell proliferation
in intestinal crypts, we first asked whether it acts by modulating
the b-catenin pathway, which is a pivotal regulator of prolifera-
tion in the intestinal epithelium (Clevers, 2006). b-catenin dis-
places the transcriptional repressor Groucho from the Tcf/Lef
complex to drive the expression of target genes in crypt stem/
progenitor cells (Clevers, 2006). We used TOPGAL reporter
mice, in which the expression of lacZ is under the control of
Tcf/Lef binding sites (DasGupta and Fuchs, 1999), to assess
whether EphB signaling influences the activity of the b-catenin
pathway. Inhibition of EphB signaling by an injection of ephrin-
B2-Fc in TOPGAL mice resulted in a significant decrease in
mRNA for the cell proliferation marker Ki67, whereas neither
lacZ mRNA levels nor the number of b-galactosidase positive
cells were altered (Figures 4A–4D).
Analysis of our microarray data for genes identified as being
under b-catenin-mediated transcriptional regulation in the col-
on (http://www.stanford.edu/rnusse/pathways/targets.html),
revealed that the level of most of these transcripts remained
unaltered after inhibiting EphB signaling by ephrin-B2-Fc injec-
tion when compared to control Fc protein (Figure 4E). The
microarray data was confirmed via quantitative RT-PCR
(qRT-PCR) for selected genes (Figure S6). Thus, EphB signaling
does not appear to have any major influence on b-catenin-
mediated transcription. These data are in line with the previous
observation that the b-catenin pathway and EphB signaling
drive cell proliferation in different domains of the crypt (Holm-
berg et al., 2006).
EphB Regulates Cyclin D1 Levels in the Intestinal
Epithelium
EphB signaling drives proliferation in intestinal crypts by
promoting cell-cycle entry (Holmberg et al., 2006). Cyclin D1 is
a regulator of cell-cycle entry, and cyclin D1 null mice display
reduced cell proliferation in intestinal crypts (Hulit et al., 2004).
Several reports suggested that cyclin D1 is a b-catenin target
gene in colon carcinoma cells in vitro (Shtutman et al., 1999;
Tetsu and McCormick, 1999). However, cyclin D1 is expressed
independently of b-catenin in vivo (Sansom et al., 2005), making
cyclin D1 a candidate target of EphB receptor signaling in the
intestinal epithelium.
Inhibition of EphB signaling by an injection of ephrin-B2-Fc
resulted in significantly reduced cyclin D1 levels in the intestine
(Figures 5A and 5B). In contrast, cyclin D2 and cyclin D3 levels
were increased (Figures 5A and 5B), which is likely to be
a result of the well-documented compensatory upregulation
when one family member is decreased (Ciemerych et al.,
2002). The alterations detected in cyclin D protein levels could
not be correlated to changes in mRNA levels 12 hr after eph-
rin-B2-Fc injection (Figures 5C and 5D), indicating that the
EphB-mediated regulation of cyclin D levels is posttranscrip-
tional.
To gain further insights into the regulation of cyclin D1, we
turned to EphB2 F620D/F620D mice. The F620D substitution
renders the catalytic domain constitutively active, independent
of ligand binding, and these mice display increased progenitor
proliferation in intestinal crypts (Holmberg et al., 2006). Cyclin
D1 protein levels were significantly increased in the intestine of
EphB2 F620D/ F620D mice, whereas the levels of cyclin D2
and cyclin D3 were reduced as compared to wild-type litter-
mates (Figures 5E and 5F).
Figure 3. EphB-Mediated Cell Positioning Is Conveyed by Phosphatidylinositol 3-Kinase
(A and B) Ls174t cells plated on a confluent mosaic of 293t cells and 293t cells expressing ephrin-B2 and GFP are preferentially found on the 293t wild-type cells.
Ls174t cells exposed to increasing concentrations of the PI3K inhibitor LY294002 lose their preference for wild-type 293t cells in a dose-dependent manner.
(C and D) In vivo administration of LY294002 results in increasing displacement of Paneth cells from 3 to 7 days compared to animals administered with vehicle.
PI3K inhibitor results in cell displacement to a similar degree as ephrin-B2-Fc, and administration of both LY294002 and ephrin-B2-Fc together does not further
accentuate this phenotype.
(E and F) Injection of ephrin-B2-Fc significantly decreases proliferation in colon crypts, whereas LY294002 administration does not. Treatment of the two inhib-
itors together does not further reduce proliferation as compared to the ephrin-B2-Fc-only treatment. n = 3 mice in each group.
Data are represented asmean + SEM. * p% 0.05, ** p% 0.01, and *** p% 0.001, Student’s t test. Scale bars represent 60 mm in (B), 10 mm in (D), and 15 mm in (F).Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc. 683
Figure 4. EphB Signaling Does Not Affect b-Catenin-Mediated Transcription
(A–D) Inhibition of EphB signaling by an injection of ephrin-B2-Fc in TOPGALmice results in a significant reduction in Ki67mRNA levels (p = 0.02, Student’s t test),
whereas b-galactosidase mRNA levels (p = 0.59) and the number of b-galactosidase-expressing cells (p = 0.30) are unaltered. Data are represented as mean +
SEM. n = 3 mice in each group.
(E) Microarray analysis reveals little effect on the expression levels of b-catenin target genes in colon 3 or 12 hr after injection of ephrin-B2-Fc compared to control
Fc protein.
* p% 0.05. The scale bar represents 10 mm.Although cyclin D1 in the intestine is easily detected by
western blot, it is difficult to localize by immunohistochemistry
in the intestinal epithelium in wild-type mice (Figure 5G). The
elevated cyclin D1 levels in the intestine of EphB2 F620D/
F620D mice were, however, readily detected and localized in
nuclei of cells in crypts (Figure 5H). As cyclin D1 is present also
in nonepithelial cells in the stroma of the intestine (Figure 5I),
which lack EphB receptor expression, the altered levels
detected in whole intestine lysates (Figures 5B and 5F) probably
underestimates the effect ofmodulating EphB signaling on cyclin
D1 levels in the epithelium.
The Mitogenic Effect of EphB Signaling Is Mediated by
Cyclin D1
To assess the relative role of cyclin D1 in EphB-mediated prolif-
eration, we inhibited EphB signaling in cyclin D1/ mice. Injec-
tion of ephrin-B2-Fc in wild-type animals significantly reduced
proliferation as compared to animals receiving control protein
(Fc) in both the small intestine and colon (Figures 5J–5M) (Holm-
berg et al., 2006). Administration of ephrin-B2-Fc to cyclin D1
null animals, however, did not reduce proliferation in either the
colon or small intestine compared to cyclin D1/mice receiving
Fc (Figures 5J–5O). Thus, EphB signaling does not have any
detectable effect on proliferation of intestinal progenitor cells in
the absence of cyclin D1, establishing cyclin D1 as a key EphB
regulated mediator of proliferation in the intestinal epithelium.
Although cyclin D1 is best known for its role in cell-cycle regu-
lation, it has also been implicated in influencing cell migration
(Li et al., 2006a, 2006b). We asked whether cyclin D1 also partic-
ipates in EphB-mediated cell positioning in intestinal crypts.
However, no displaced Paneth cells were found in cyclin D1
null mice, and EphB2-immunoreactive progenitor cells were
organized as in wild-type mice (Figure S7). Thus, cyclin D1medi-
ates the effects of EphB signaling on proliferation, but not migra-
tion, in the intestinal epithelium.684 Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc.EphB Regulates Cyclin D1 Levels and Proliferation via
Abl
Abl binds to EphB4 in an activity-dependent manner and regu-
lates proliferation and tumorigenicity in breast cancer cell lines
(Noren et al., 2006). We asked whether Abl is involved in EphB-
mediated regulation of cyclin D1 and cell proliferation in the
intestinal epithelium.
We first suppressed Abl levels by transfecting epithelial cells
with Abl short hairpin RNA (shRNA) in intestinal explants by elec-
troporation. This resulted in a significant reduction in the number
of proliferating cells (Figures 6A and 6B). We next assessed cell
proliferation in the intestinal epithelium inAbl/mice.Thenumber
ofBrdU-labeledproliferatingcellswas reduced toa similar degree
as after blockage of EphB signaling or deletion of cyclin D1 in both
the small intestine and colon (Figures 6C and 6D). Administration
of the Abl kinase inhibitor Gleevec (imatinibmesylate) significantly
reduced cyclin D1 protein levels compared to animals injected
with vehicle (Figures 6E and 6F), without affecting EphB2 phos-
phorylation (Figure S8). TOPGAL mice showed an approximately
50%decrease inKi67mRNA,whereas the levelof lacZmRNAwas
unaffected after Gleevec injection (Figure 6G). Thus, similarly to
EphBsignaling, Abl regulates cyclinD1 levels andcell proliferation
in the intestinal epithelium, without significantly affecting the
b-catenin signaling pathway.
We next asked whether Abl conveys themitogenic signaling of
EphB receptors. Ephrin-B2-Fc and Gleevec reduced the number
of dividing progenitor cells in both the small intestine and colon
to a similar extent (Figures 6H and 6I). However, administration
of ephrin-B2-Fc and Gleevec together had no additive effect
and did not further reduce proliferation (Figures 6H and 6I).
Furthermore, Gleevec had no effect on proliferation in cyclin
D1/ mice (Figure 6J), establishing that cyclin D1 is required
for Abl to mediate mitogenic signals. We quantified the number
of Tunel-positive dying cells, but could not detect any significant
differences in apoptosis that could explain the observed
reduction in proliferation in response to ephrin-B2-Fc, Gleevec,
or ephrin-B2-Fc and Gleevec when compared to control animals
(Figure S9).
Cell proliferation is increased in the intestinal epithelium of
mice with a modified (F620D) constitutively active EphB2
receptor (Holmberg et al., 2006) (Figure 6K). Administration of
Gleevec to EphB2F620D/F620D mice reduced the proliferation
of intestinal epithelial cells, and, most importantly, there was
no difference in the number of BrdU-labeled cells compared to
wild-type mice receiving Gleevec (Figure 6K). Thus, the effect
of increased EphB2 kinase activity on cell proliferation can be
abolished by Gleevec.
Abl has been implicated in conveying EphA-mediated growth
cone collapse (Harbott and Nobes, 2005). Does Abl, in addition
to mediating the mitogenic effects of EphB signaling, control
cell positioning in the intestinal epithelium? The Paneth cells of
the small intestine are displaced 3 days after an ephrin-B2-Fc
injection, mimicking the phenotype of EphB2/; EphB3/
mice (Figures 6L–6O). Administration of Gleevec for three
consecutive days resulted in sustained reduced proliferation
Figure 5. Cyclin D1 Is Required for the Mitogenic Effect of EphB
(A and B) Western blot analysis of cyclin D levels in the colon after inhibition of EphB signaling with ephrin-B2-Fc compared to vehicle (PBS).
(C and D) mRNA levels for cyclin D family members are not altered after an injection of ephrin-B2-Fc as assayed by qRT-PCR (C, at 12 hr after ephrin-B2-Fc
injection) or microarray analysis (D).
(E and F) Western blot analysis of cyclin D levels in the colon in wild-type (Wt) mice and in mice with a modified (F620D/F620D) constitutively active EphB2
receptor.
(G and H) Cyclin D1 levels are too low to be detected by immunohistochemistry in wild-type mice, but are readily detected in cell nuclei in colon crypts in EphB2
F620D/F620D mice.
(I) Cyclin D1-positive cells are detected in the stroma of wild-type small intestine (arrowheads).
(J and K) Quantification of Ki67-immunoreative cells in crypts of the small intestine and colon reveals a similar degree of reduction in the number of proliferating
cells in cyclin D1/mice and in animals receiving an ephrin-B2-Fc injection (24 hr prior to analysis) compared to wild-type animals receiving control Fc protein.
Administration of ephrin-B2-Fc does not reduce proliferation further in cyclin D1/ mice.
(L–O) Ki67-immiunoreactive cells in the crypts of the small intestine.
n = 3mice in each group, except n = 2 in some cyclin D1/ groups. Data are represented asmean +SEM. Scale bars represent 10 mm in (G) and 30 mm in (I). ** p%
0.01 and *** p% 0.001, Student’s t test.Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc. 685
Figure 6. Proliferation, but Not Migration, Is Mediated by Abl
(A and B) Electroporation of Abl shRNA in intestinal explants leads to a reduction in the number of electroporated cells (GFP expressing) incorporating BrdU.
(C and D) Proliferation in the Abl mutant mouse is reduced in both small intestine and colon.
(E and F) Gleevec (100 mg/kg) leads to a decrease in cyclin D1 protein levels in the colon detected by western blot analysis.
(G) Administration of Gleevec to TOPGAL mice leads to a 50% reduction in Ki67 transcript, without affecting the expression of b-galactosidase (p = 0.87).
(H and I) Inhibition of Abl with Gleevec or ephrin-B2-Fc reduces cell proliferation in the small intestine and colon to a similar extent, but there is no additive effect.
(J) Gleevec does not affect cell proliferation in colon crypts in cyclin D1/ mice.
(K) Analysis of EphB2 F620D/F620D mice with constitutively active EphB2 receptors reveals an increase in the number of BrdU-positive cells compared to wild-
type littermates. Administration of Gleevec to wild-type and EphB2 F620D/F620D mice results in a suppression of proliferation to the same level in both geno-
types.686 Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc.
(Figure S10), but did not cause defects in cell positioning
(Figure 6L and 6P). Moreover, analysis of Paneth cell distribution
in Abl/mice did not reveal any evidence for cell displacement
(Figures 6L and 6Q). Thus, the Abl pathway transduces the
EphB-mediated regulation of cyclin D1 and cell proliferation,
but does not affect cell positioning.
Dissociation of EphB Signaling from Cyclin D1 during
Tumor Progression
A common initial step in human colon cancer formation is gain-
of-function mutations in the b-catenin pathway and adenoma
formation (Clevers, 2006). EphB2 and EphB3 are targets of
b-catenin-mediated transcription, resulting in highly proliferative
and EphB-expressing cells in adenomas (Batlle et al., 2002). We
turned to the APCmin mouse model of adenomatous polyposis to
study the role of EphB signaling in adenomas. Untransformed
epithelial crypt cells in APCmin/+ mice are heterozygous for muta-
tions rendering the b-catenin pathway constitutively active,
resulting in increased proliferation compared to wild-type mice.
We detected a significant reduction in proliferation in the intact
crypts in both the small intestine and colon 24 hr after an eph-
rin-B2-Fc or Gleevec injection in APCmin/+ mice (Figures 7A
and 7B). Adenomas develop in both the colon and small intestine
in APCmin/+ mice as cells lose APC heterozygosity. Both ephrin-
B2-Fc and Gleevec reduced proliferation in adenomas by more
than 50% (Figure 7C) and resulted in a depletion of cyclin D1 in
adenoma cells (Figures 7D–7F).
Ephrin-B-expressing cells in the intact tissue encapsulate the
EphB-expressing adenoma cells and form a repulsive barrier
preventing the transformed cells from entering the surrounding
normal tissue. The expression of EphB receptors is frequently
lost during the progression of colorectal cancer in humans,
and this correlates with a poor prognosis (Batlle et al., 2005;
Guo et al., 2005; Jubb et al., 2005). Loss of EphB signaling allows
invasive growth, but how can proliferation be maintained at
a high level when EphB receptor expression is lost? To under-
stand more about the adenoma to carcinoma transition, we
analyzed EphB2, cyclin D1 and PCNA protein levels in human
tumor samples (Figure 7G and Table S3). EphB2 levels were
significantly reduced in carcinomas compared to adenomas,
as previously reported (Batlle et al., 2005; Guo et al., 2005;
Jubb et al., 2005). In spite of this, both the proliferation marker
PCNA and cyclin D1 remained at a similar level in carcinomas
as in adenomas. Cyclin D1 levels and proliferation correlate
strongly with EphB signaling in untransformed intestinal epithe-
lial progenitor cells and in adenoma cells. This correlation is
lost at the stage of transformation from adenoma to carcinoma,
indicating that cyclin D1 expression becomes independent of
EphB2 in human colon carcinoma (Figure 7H).
To more directly study the role of EphB signaling in regulating
cyclin D1 levels in human transformed intestinal cells, we
assessed the regulation of cyclin D1 in response to ephrin-B2in Ls174t cells (which express high levels of EphB2 and
EphB3, like adenoma cells) and KM12 cells (with little or no
expression of EphB receptors, like carcinoma cells). We found
that mixing Ls174t cells with 293t cells expressing ephrin-B2 re-
sulted in significantly elevated cyclin D1 levels compared to cells
mixed with wild-type 293t cells, whereas there was no significant
change in the cyclin D1 levels in KM12 cells in response to eph-
rin-B2 (Figures 7I and S11). Thus, cyclin D1 regulation becomes
dissociated from EphB signaling during the transition from
adenoma to carcinoma, allowing continued high proliferation
with the additional capacity for invasive growth.
To gain insight into the regulation of cyclin D1 in the absence of
EphB receptor expression in colon carcinoma, we first asked
whether Gleevecmay affect cyclin D1 levels and cell proliferation
in HT-29 and KM12 human colon carcinoma cells. HT-29 cells
lack EphB2 and EphB3 receptor expression but express
EphB4, and KM12 cells have little or no expression of EphB
receptors (Batlle et al., 2005; Davalos et al., 2006). Gleevec
significantly reduced BrdU incorporation and cyclin D1 levels
in HT-29 and KM12 cells (Figures 7J–7L). Moreover, Abl shRNA
reduced cyclin D1 levels in HT-29 cells (Figures 7M, 7N, and
S12). Thus, in contrast to in the untransformed intestinal epithe-
lium, where Abl activity is strictly under the control of EphB
signaling (Figure 6), Abl appears independent of EphB signaling
in human colon carcinoma cells.
Many reports have demonstrated mitogenic effects and over-
activation of the EGF and IGF receptor pathways in human colon
carcinoma, and monoclonal blocking antibodies to the EGF
receptor are used to treat colon cancer in humans (Ciardiello
and Tortora, 2008; Donovan and Kummar, 2008). Both
EGF and IGF receptors activate Abl in other contexts (Srinivasan
and Plattner, 2006; Srinivasan et al., 2008). We found that the
EGF receptor inhibitor PD153035 significantly reduced cyclin
D1 levels and proliferation of HT-29 cells and that the IGF
receptor inhibitor AEW-541 reduced cyclin D1 levels and prolif-
eration in KM12 cells (Figures 7O–7R and S13). This indicates
that EGF and IGF receptor signaling, at least in part, can
compensate for the loss of EphB expression to maintain cyclin
D1 levels and proliferation after the progression from adenoma
to carcinoma.
DISCUSSION
We show here that EphB receptors engage distinct signaling
pathways in the intestinal stem cell niche to regulate cell prolifer-
ation and migration. EphB receptors regulate cell positioning in
the intestinal epithelium via PI3K, independently of kinase
activity. In contrast, intrinsic EphB tyrosine kinase activity drives
proliferation in crypt progenitor cells through Abl, resulting in
posttranscriptional regulation of cyclin D1 protein levels. EphB
signaling promotes cell proliferation in adenomas and simulta-
neously inhibits invasive growth. At the progression from(L–Q) Paneth cells, visualized by lysozyme (Lys) immunoreactivity, are displaced in EphB2; EphB3 double-null mutant animals. Inhibition of EphB signaling with
ephrin-B2-Fc also results in displaced Paneth cells 3 days after an injection. In contrast, animals receiving Gleevec for three consecutive days as well as Abl/
mice show no evidence of Paneth cell displacement.
n = 3–6 mice in each group, except n = 2 cyclin D1/mice receiving Gleevec. Data are represented as mean + SEM. * p% 0.05, ** p% 0.01, and *** p% 0.001,
Student’s t test. The scale bar represents 10 mm.Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc. 687
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adenoma to carcinoma, cyclin D1 expression becomes indepen-
dent of EphB signaling, explaining how high proliferation can be
maintained and accompanied by invasive growth after loss of
EphB expression.
Pathways Regulating Proliferation and Migration
Diverge at the EphB2 Receptor
The analysis of the intestinal transcriptome after acute inhibition
of EphB signaling provided a first indication that cell migration
and proliferation may be regulated independently. The EphB-
mediated regulation of proliferation appears to be mainly post-
transcriptional, whereas the transcription of key components
regulating cell positioning is rapidly altered after inhibition of
EphB signaling. The generation of mutant mice with different
EphB2 modifications established that these pathways diverge
at the level of the receptor protein.
We find that whereas EphB intrinsic kinase activity conveys
mitogenic signals, cell positioning is regulated by kinase-inde-
pendent forward signaling. There are naturally occurring Eph
receptors that lack kinase activity, as well as kinase-inactive
spliced versions of some receptors that can modulate the kinase
activity of full-length catalytically functional receptors (Holmberg
et al., 2000). There are previous examples of kinase-dependent
and -independent signaling by the same Eph receptor in vitro
(Gu and Park, 2001; Miao et al., 2005). It is clear that Eph recep-
tors convey directional signals to regulate cell migration or
axon guidance in divergent ways in different contexts. For
example, in contrast to kinase-independent cell positioning in
the intestinal epithelium, the EphA4 kinase domain is required
for the correct guidance of certain axons (Dufour et al., 2006;
Kullander et al., 2001).
The EphB Paradox Is Explained by the Independent
Regulation of Migration and Proliferation
The recent recognition of the similarities between untransformed
stem/progenitor cells and cancer cells has provided a mecha-
nistic explanation for the inherent difficulty in developing strate-
gies to eradicate tumor cells without interfering with tissuehomeostasis. Identification of signaling pathways that have
divergent effects in tissue stem/progenitor cells and cancer cells
may offer insights into cancer development as well as offer novel
therapeutic targets. EphB receptors are interesting in this
context since they promote cell proliferation in the intact intes-
tinal epithelium as well as in adenomas, but still act as tumor
suppressors for colon carcinoma development. The tumor
suppressor function of EphB receptors is a result of their regula-
tion of cell migration and compartmentalization of tumor cells
(Cortina et al., 2007). These dual functions, regulation of cell
proliferation and migration, result in EphB receptors driving
proliferation but still acting as tumor suppressors. The loss of
EphB expression during carcinogenesis enables invasive
growth. In parallel, cyclin D1, which is regulated by EphB kinase
activity in intestinal progenitors and is the effector of EphB mito-
genic signaling, becomes independent of EphB signaling and
continues to promote proliferation in colon carcinoma cells.
Thus, the fact that EphB receptors engage separate signaling
pathways to regulate proliferation and migration is the basis for
the paradoxical proliferative and tumor suppressor functions of
the same protein.
A Pharmacological Strategy to Inhibit Adenoma Growth
The dissociation of signaling pathways for EphB-mediated
migration and proliferation enabled the identification of Gleevec
as an inhibitor specifically of EphB mitogenic signaling, without
affecting cell migration. Cyclin D1 is the effector of EphB-medi-
ated proliferation and inhibiting EphB signaling with soluble eph-
rin or Gleevec was equally efficient in reducing cyclin D1 levels
and cell proliferation. Analysis of APCmin mice hetero- or homo-
zygous for cyclin D1 null alleles has established that the level of
cyclin D1 is an important determinant of tumor number and
adenoma cell proliferation (Hulit et al., 2004).
Familial adenomatous polyposis (FAP) patients develop large
numbers of adenomas and have highly increased risk of devel-
oping colon carcinoma (Lynch, 2007). The colon is often
removed in FAP patients to avoid carcinoma development, and
pharmacological alternatives to reduce adenoma growth inFigure 7. Dissociation of EphB Signaling Pathways during Tumor Progression
(A–C) Inhibition of EphB signaling with ephrin-B2-Fc or administration of Gleevec in APCmin mice reduces the number of BrdU-incorporating cells in untrans-
formed crypts in the small intestine (A) and colon (B), as well as in adenomas (C).
(D–F) Adenomas in APCmin mice display high levels of cyclin D1 compared to the surrounding tissue (D). Inhibition of EphB signaling with ephrin-B2-Fc (E) or
Gleevec (F) in APCmin mice leads to reduced cyclin D1 levels in adenomas. Boxed areas are shown in higher magnification.
(G) Analysis of protein levels by western blot in human colon adenoma and carcinoma samples. All values were normalized to neighboring untransformed tissue
from the same patient. EphB2 receptor expression is high in adenomas. At the transition to carcinoma, EphB2 is downregulated and the proliferation marker
PCNA and cyclin D1 are maintained independently of EphB expression.
(H) The ratio of cyclin D1/EphB2 protein changes at the transition from colon adenoma to carcinoma, and there is no significant further change during the progres-
sion to more advanced UICC cancer stages.
(I) Ls174t cells expressing EphB2 and EphB3 receptors display a significant increase in cyclin D1 levels after being plated together with 293t cells expressing
ephrin-B2, as compared to Ls174t cells plated together with wild-type 293t cells. KM12 cells, expressing no or low levels of EphB receptors, do not upregulate
cyclin D1 when plated together with ephrin-B2 expressing cells.
(J–L) HT-29 andKM12 cells treatedwithGleevec for 48 hr display a reduced number of BrdU-positive cells compared to cells treatedwith vehicle. Gleevec admin-
istration also results in reduced levels of cyclin D1 in both cell lines.
(M and N) HT-29 cells transfected with shRNA against Abl with GFP display significantly reduced levels of cyclin D1 after 24 hr compared to cells transfected with
GFP only.
(O–R) Administration of EGF (PD153035) or IGF (AEW-541) receptor inhibitor to HT-29 or KM12 colon carcinoma cell lines results in reduced proliferation in both
cell lines, whereas PD135035 only affects cyclin D1 in HT-29 cells and AEW-541 only in KM12 cells.
Data are represented as mean + SEM. n = 3–4 mice in each group. All in vitro experiments were made in triplicate. The scale bar represents 50 mm. * p% 0.05,
** p% 0.01, and *** p% 0.001, Student’s t test.Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc. 689
FAP and other patients with high risk of developing colon carci-
noma would be very attractive (Lynch, 2007). The strong influ-
ence of reduced cyclin D1 levels on tumor number in APCmin
mice, which is an animal model of FAP, lead to the suggestion
that cyclin D1 may be an attractive target for pharmacological
intervention (Hulit et al., 2004). We show that administration of
the Abl inhibitor Gleevec reduces cyclin D1 levels and decreases
proliferation in the intestinal epithelium to the same degree as in
cyclin D1/ mice. Gleevec is rather well tolerated and is given
chronically to patients, although it remains to be studied whether
a similar Gleevec dose would be sufficient to suppress prolifera-
tion in adenomas. The development of inhibitors restricted to
inhibiting Abl’s interaction with EphB receptors would likely
reduce the side effects substantially compared to Gleevec. Inhi-
bition of EphB-mediated proliferation may offer a pharmacolog-
ical alternative to removal of the colon in patients with FAP and
other similar conditions to reduce adenoma growth and poten-
tially cancer progression.
EXPERIMENTAL PROCEDURES
Animals
Tissues from all Eph receptor mutant mice on CD1 genetic background were
coded by genotype in the M.H. laboratory, and all analyses were done blind to
genotype in the J.F. laboratory. The generation of new EphB2 mouse mutants
was made by homologous recombination in embryonic stem cells as
described in detail in the Supplemental Data. Adult male C57/Bl6 mice were
used for all injection experiments. The mice received either 100 mg of ephrin-
B2-Fc in PBS (repeated at day 3 for animals analyzed at day 7), administered
through the tail vein, or intraperitoneal injection of Gleevec (Imatinib mesylate,
Novartis) at a concentration of 100 mg/kg. Gleevec was administered every
12th hour to animals sacrificed after 24 hr and once a day to animals sacrificed
after 72 hr. LY294002 was administered intraperitoneally once daily at
a concentration of 30 mg/kg. Two hours before sacrifice, animals received
BrdU (100 mg/kg 0.09% NaCl in PBS).
Microarray Analysis
Total RNA was extracted from rinsed colons with Trizol (Invitrogen). Affymetrix
Gene Chip Mouse Genome 430A 2.0 was used for the hybridization, and all
data were analyzed with GeneSifter, Panther, or GOTM software (http://
bioinfo.vanderbilt.edu/gotm/). All samples were normalized according to the
Affymetrix MAS5method, after which we applied the MultiDimentional Scaling
approach in order to appreciate differences between the samples. The
samples clustered into three groups (Figure S14). All data are available with
ArrayExpress accession E-TABM-753.
Immunohistochemistry
Cryosections were incubated with primary antibody at 4C over night, washed
in PBS, and then incubatedwith a secondary antibody. All antibodies are spec-
ified in the Supplemental Data.
Western Blot Analysis
Tissue taken for western blot analysis was put in ice-cold lysis buffer (1 M Tris
[pH 8], 5MNaCl, 10%NP-40, 10%SDS, 10%Na desoxycholate in H20), mixed
with Complete protease inhibitor cocktail (Roche) and homogenized with
a rotor. Lysates were either analyzed directly with the NuPage blot system
(Invitrogen) or used for immunoprecipitation with anti-EphB2 (0.2 mg/100 ml
lysate) for 4 hr on ice and then pulled down with Protein A/G sepharose (Amer-
sham) for 1.5 hr on ice. Normalization was performed in two steps. All samples
were first normalized to either b-actin or GAPDH, after which the mean value
for each group was calculated and the experimental group was normalized
against the control group.690 Cell 139, 679–692, November 13, 2009 ª2009 Elsevier Inc.Quantitative PCR
RNA extraction was done with Trizol according to the manufacturer’s protocol.
For the reverse-transcription reaction, SuperScript III First Strand (Invitrogen)
was used. mRNA levels were measured by relative quantification via the stan-
dard curve method on a 7300 Real-Time PCR System from Applied Biosys-
tems. The standard was made from Mouse Reference Total RNA (Stratagene
QPCR). b2-microglobulin was used as the internal control against which all
individual samples were normalized.
In Vitro Cell Positioning Assay
293t cells and 293t-ephrin-B2-GFP-expressing cells were mixed at a 2:1 ratio
and plated in a 24-well plate at a density of 1.33 104 cells/cm2. The cells were
cultured for up to 48 hr until they reached confluency. Ls174t colon carcinoma
cells were labeled with DiD (Molecular Probes) and plated on top of the 293t
mosaic at a density of 50,000 cells/well. LY294002 was added to the cultures
and the cells were fixed with 4% formaldehyde 18 hr later.
Quantitative Assessment of In Vivo Cell Positioning
Quantification of Paneth cell positioning was done by measurement of the
distance of each Paneth cell from the crypt bottom. The average distance
for each crypt was calculated by division of the total distance per crypt by
the total number of Paneth cells per crypt. The positioning of neuroendocrine
cells and goblet cells was assessed by quantification of the number of respec-
tive cell type within the crypt. The length occupied by Ki67+ cells in the crypt
was measured to assess the distribution of proliferating progenitor cells.
Cell Culture
HT-29 and Ls174t cells were obtained from the American Type Culture Collec-
tion and KM12 cells fromNational Cancer Institute/National Institutes of Health
(NIH). Nontoxic concentrations for all inhibitors were determined by dilution
series. Cells were exposed to BrdU (10 mM) for 30 min before they were fixed
with 4% formaldehyde or lysed with western blot lysis buffer. Ls174t or KM12
cells were labeled with DiD (V22889,Molecular Probes) andmixed at a 1:1 ratio
with either 293t or 293t-ephrin B2-GFP-expressing cells and plated in 6-well
plate at a density of 5.5 3 105 cells/cm2. At this density, cells cover the entire
plate after attachment and are forced to interact with each other. The colon
carcinoma cells were FACS purified 18 hr later based on the DiD expression
and put in lysis buffer for analysis.
Transfections
shRNAs for Abl-1 (Invitrogen) were subcloned into a GFP-containing expres-
sion plasmid. Constructs were evaluated by transfection of 3T3 cell lines
with Lipofectamine 2000 according to themanufacturer’s protocol, after which
transfected and nontransfected cells were FACS purified and analyzed by
qRT-PCR for Abl RNA expression. Transfection of HT-29 cells was also per-
formed with Lipofectamine 2000, and 24 hr later, cells transfected with either
GFP only or Abl shRNAGFPwere FACS purified and analyzed by western blot.
Small intestine from embryonic day 15 mouse embryos were dissected out,
and expression plasmids for Abl shRNA and GFP or GFP only (10 mg/ul in PBS)
were injected into the lumen of a 0.5 cm intestinal segment. The tissue was
submerged in PBS and electorporated with five pulses (50 ms and 60 V)
with a CUY21 EDIT electroporator (Sonidel). The tissue segments were kept
in hanging cultures in DMEM:F12 with 10% FBS and 1% penicillin/strepto-
mycin for 15 hr. BrdU (40 mg/mL) was added to the cultures for 1 hr before fixa-
tion in 4% formaldehyde.
Human Tumor Tissue
Adenoma and adenocarcinoma (Union Internationale Contre le Cancer [UICC]
stage I–IV) tissue samples were collected during colonoscopy or surgery,
frozen in liquid nitrogen, and stored at 70C until analysis.
ACCESSION NUMBERS
All original data have been uploaded with Tab2MAGE submission to Array-
Express in compliance with MIAME standards (ArrayExpress accession
number E-TABM-753).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 14
figures, and three tables and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)01188-X.
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